Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Anteris Technologies Ltd operates as a structural heart company. It manufactures and sells ADAPT, a regenerative tissue product. The company also engages in the developing of DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. In addition, it researches and develops regenerative medicines. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of AVR.AX is 10.0 and suggests 37% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell